Welcome
Support Centre
30 July 2010 
Current Controlled Trials - Clinical Trials
Trial registration
Unique identification scheme
International databases
home  |   my details  |   ISRCTN Register  |   mRCT  |   links  |   information  |   news
Introduction
English introduction Introduction en français Deutsche einleitung
Introducción española Introduzione in italiano
 
Find trials
active registers
mental health register
archived registers
all registers
tips on searching
 
 
Information
about mRCT
mRCT FAQs

DISCLAIMER
The site should not be used to diagnose or treat a health problem. Please consult your doctor.
Terms & conditions

DUPLICATION
Your search result may contain a number of different records for the same trial. This occurs when the same trial is listed in more than one register.

[ ...Back to search results ] [ Print-friendly version ]
A randomised study of oral versus intravenous chemotherapy in poor prognosis small cell lung cancer (SCLC)
Source of recordUK Trials
ISRCTNISRCTN73797340
Date ISRCTN assigned01/07/2001
Local reference number(s)TR9SCLC
Public titleA randomised study of oral versus intravenous chemotherapy in poor prognosis small cell lung cancer (SCLC)
Scientific title
AcronymNot Applicable
Disease/condition/study domainLung (small cell)
Study hypothesisNot provided at time of registration
Design/methodologyRandomised controlled trial
Research ethics reviewNot provided at time of registration
Countries of trialUnited Kingdom
Participants - inclusion criteria1. Histologically or cytologically proven SCLC
2. Patients with extensive disease and poor prognosis, ie Eastern Cooperative Oncology Group (ECOG) performance 2 or 3 or alkaline phosphatase >1.5 upper limit normal range
3. Patients 75 years and over, whatever stage of disease, deemed fit for randomisation
4. No previous malignancy, except non melanomatous skin cancer in the preceding 3 years
5. No medical contraindications to treatment
6. Adequate renal function
Participants - exclusion criteriaNot provided at time of registration
Patient information material
Status of trialCompleted
Target number of participantsNot provided at time of registration
Interventions1. Regimen A: Chemotherapy, oral etoposide repeated every 3 weeks for six courses.
2. Regimen B: Multi-drug chemotherapy, CAV (cyclophosphamide, adriamycin, vincristine) alternating every 3 weeks with PE (etoposide, cisplatin). A total of six courses, three with each drug combination.
Primary outcome measure(s)Not provided at time of registration
Secondary outcome measure(s)Not provided at time of registration
Sources of fundingNot available
Sponsor nameUK Co-ordinating Committee for Cancer Research (UKCCCR)
Sponsor detailsMRC Clinical Trials Unit
222 Euston Road
London
United Kingdom
NW1 2DA
Sponsor telephone+44 (0) 20 7670 4723
Sponsor fax+44 (0) 20 7670 4818
Sponsor emailregister@ctu.mrc.ac.uk
Sponsor websitehttp://www.ctu.mrc.ac.uk/ukcccr/home.html
Contact nameDr - -
Contact detailsUKCCCR Register Co-ordinator
MRC Clinical Trials Unit
222 Euston Road
London
United Kingdom
NW1 2DA
Contact telephone+44 (0) 20 7670 4723
Contact fax+44 (0) 20 7670 4818
Contact emailregister@ctu.mrc.ac.uk
More informationFor more up-to-date information please go to the ISRCTN link below.
Link to record in ISRCTN RegisterISRCTN73797340
Date last extracted from ISRCTN register17/04/2008
Submit your trial protocol
Submit to Trials journal
Follow us on Twitter
© 2010 Current Controlled Trials Ltd. Part of Springer Science+Business Media. | terms & conditions | privacy statement


BioMed Central